There is some evidence that anti-IL-17 antibodies reduce the progression of pancreatic intraepithelial neoplasia and metastasis and enhance the effectiveness of anti-VEGF in colorectal cancer treatment [18,104]. Here, IL17A is linked to colorectal cancer.